Related Experiment Video
Updated: Jun 17, 2026
08:04
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Functional characterization of two human receptor activity-modifying protein 3 variants
Richard J Bailey1, Joshua W I Bradley, David R Poyner
1School of Biological Sciences, University of Auckland, Symonds Street, Auckland, New Zealand. Rj.bailey@auckland.ac.nz
Peptides
|December 26, 2009
Summary
RAMP3 variants, including Cys40Trp and Phe100Ser mutations, impair adrenomedullin and amylin receptor function by reducing cell-surface expression. However, the Trp56Arg variant shows normal function, highlighting specific RAMP3 roles.
Area of Science:
- Molecular biology
- Biochemistry
- Genetics
Background:
- Adrenomedullin (AM) and amylin are key regulators of angiogenesis and glucose homeostasis, respectively.
- These peptides signal through receptor activity-modifying protein (RAMP)/G protein-coupled receptor (GPCR) complexes, including RAMP3-based AM(2) and AMY(3) receptors.
- The functional consequences of RAMP3 sequence variations on receptor activity are not well understood.
Purpose of the Study:
- To investigate the functional impact of specific RAMP3 variants, including those identified in the AK222469 mRNA sequence and the polymorphic Trp56Arg variant.
- To elucidate the role of specific amino acid residues within RAMP3 in receptor complex formation and signaling.
Main Methods:
- Wild-type (WT) human RAMP3 was used as a template to introduce specific amino acid mutations (Cys40Trp, Phe100Ser, Leu147Pro, Trp56Arg).
- Mutant and WT RAMP3 constructs were expressed in Cos-7 cells with either the calcitonin receptor-like receptor (CLR) or the calcitonin receptor (CT(a)).
- Functional assays were performed to assess AM and amylin potency at the respective AM(2) and AMY(3) receptor complexes, alongside cell-surface expression analysis.
Main Results:
- The Cys40Trp/Phe100Ser/Leu147Pro RAMP3 variant exhibited compromised function, with significantly reduced potency for both AM and amylin.
- Cys40Trp and Phe100Ser mutations were identified as the primary contributors to the functional deficit, while Leu147Pro had minimal impact.
- Reduced cell-surface expression of the mutant RAMP3/GPCR complexes was observed, correlating with the functional impairment. The Trp56Arg RAMP3 variant displayed WT-like function.
Conclusions:
- Specific RAMP3 mutations, particularly Cys40Trp and Phe100Ser, disrupt AM and amylin receptor function, likely due to impaired cell-surface expression.
- The Trp56Arg RAMP3 variant is functionally normal, indicating that not all sequence variations affect receptor activity.
- These findings provide critical insights into RAMP3 structure-function relationships and have implications for understanding human health conditions associated with RAMP3 variations.
Related Concept Videos
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:57Protein Complexes with Interchangeable Parts
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:04Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
01:30Transducer Mechanism: G Protein–Coupled Receptors
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
GPCRs are also called heptahelical, 7TM, or...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...